Who is sponsoring NCT00424697?

NCT00424697 is sponsored by GlaxoSmithKline.

What condition does NCT00424697 study?

NCT00424697 studies Healthy Subjects.

What drugs are being tested in NCT00424697?

Interventions: placebo, lorazepam, GW876008.

What is the status of NCT00424697?

NCT00424697 is currently COMPLETED.

Last reviewed 2010-10-13 · How we verify

A Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GW876008 and Lorazepam (Comparator) in Healthy Subjects.

NCT00424697 Phase 1 COMPLETED

Data suggests that imaging activity of the brain can measure the effects of anti-anxiety drugs. This study will investigate the effect of GW876008 on areas of the brain involved with thinking and emotion

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	COMPLETED
Enrolment	26
Start date	2007-03
Completion	2007-12

Conditions

Healthy Subjects

Interventions

placebo
lorazepam
GW876008

Primary outcomes

Differences in brain activation elicited by Matching Emotional Face Expression paradigm following single oral doses of GW876008 and lorazepam on day 1, sessions 1-4

Countries

United States